Posted by Michael Wonder on 17 Nov 2016
TGA approves Ninlaro
17 November 2016 - The TGA has approved Takeda's proteasome inhibitor for use by patients with multiple myeloma.
The TGA approved ixazomib citrate on 15 November 2016 for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
The TGA approved indication for Ninlaro is consistent with its label in the US and the EU.
